3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Glioma
4
Sarcoma
3
Wilms Tumor
2
Thyroid Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Multiple Myeloma
2
Melanoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lung Neoplasms
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Ependymoma
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Xanthogranuloma, Juvenile
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Interventions
Cisplatin
15
Gemcitabine
14
durvalumab
10
pembrolizumab
7
Oxaliplatin
6
Bevacizumab
6
Capecitabine
5
lenvatinib
4
Nivolumab
4
S 1 (combination)
3
Liquid Biopsy
3
Irinotecan
3
Folfox protocol
3
Fluorouracil
3
Carboplatin
3
zanidatamab
2
tremelimumab
2
envafolimab
2
Trastuzumab
2
Leucovorin
2
Injections
2
Blood Specimen Collection
2
Albumin-Bound Paclitaxel
2
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
poly ICLC
1
niraparib
1
neratinib
1
larotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
larotrectinib
×
90 days
×
Clear all
NCT02576431
2026-04-28
NAVIGATE
Bayer
Phase 2
Completed
215 enrolled
2 FDA